Annals ofAntibiotics

Volume: 1 - Number: 1 - December 15, 2003

Outstanding

Drug Targeting Mycobacterium tuberculosis Cell Wall Synthesis: Development of a Microtiter Plate-Based Screen for UDP-Galactopyranose Mutase and Identification of an Inhibitor from a Uridine-Based Library

High Variability of Plasma Drug Concentrations in Dual Protease Inhibitor Regimens

Aminoglycoside Efflux in Pseudomonas aeruginosa: Involvement of Novel Outer Membrane Proteins

Low-Level Resistance to Rifampin in Streptococcus pneumoniae

Actions Mechanism: Physiological Effects

Alteration of Escherichia coli Topoisomerase IV to Novobiocin Resistance

Drug Targeting Mycobacterium tuberculosis Cell Wall Synthesis: Development of a Microtiter Plate-Based Screen for UDP-Galactopyranose Mutase and Identification of an Inhibitor from a Uridine-Based Library

Antiviral`s agents

Activation and Deactivation of a Broad-Spectrum Antiviral Drug by a Single Enzyme: Adenosine Deaminase Catalyzes Two Consecutive Deamination Reactions

Experimental Therapeutics

Activities of Moxifloxacin Alone and in Combination with Other Antimicrobial Agents against Multidrug-Resistant Mycobacterium tuberculosis Infection in BALB/c Mice

Activities of Moxifloxacin against, and Emergence of Resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an In Vitro Pharmacokinetic Model

Activity and Diffusion of Tigecycline (GAR-936) in Experimental Enterococcal Endocarditis

Garenoxacin (BMS-284756) and Moxifloxacin in Experimental Meningitis Caused by Vancomycin-Tolerant Pneumococci

Modifier of the Biological Response

High Variability of Plasma Drug Concentrations in Dual Protease Inhibitor Regimens

Pharmacology

ABT-773: Pharmacokinetics and Interactions with Ranitidine and Sucralfate

Resistence mechanism

Active-Site Residues of Escherichia coli DNA Gyrase Required in Coupling ATP Hydrolysis to DNA Supercoiling and Amino Acid Substitutions Leading to Novobiocin Resistance

A Point Mutation in the 14-Sterol Demethylase Gene cyp51A Contributes to Itraconazole Resistance in Aspergillus fumigatus

A New Sulfonamide Resistance Gene (sul3) in Escherichia coli Is Widespread in the Pig Population of Switzerland

A Clonal Lineage of VanA-Type Enterococcus faecalis Predominates in Vancomycin-Resistant Enterococci Isolated in New Zealand

Amino Acid Sequence Requirements at Residues 69 and 238 for the SME-1 ß-Lactamase To Confer Resistance to ß-Lactam Antibiotics

Aminoglycoside Efflux in Pseudomonas aeruginosa: Involvement of Novel Outer Membrane Proteins

Diversity of Tetracycline Resistance Genes in Bacteria from Chilean Salmon Farms

Exploring the Structure and Function of the Mycobacterial KatG Protein Using trans-Dominant Mutants

Low-Level Resistance to Rifampin in Streptococcus pneumoniae

Mutant Prevention Concentration of Garenoxacin (BMS-284756) for Ciprofloxacin-Susceptible or -Resistant Staphylococcus aureus

Susceptibility

Activities of the Glycylcycline Tigecycline (GAR-936) against 1,924 Recent European Clinical Bacterial Isolates

Activities of Temporin Family Peptides against the Chytrid Fungus (Batrachochytrium dendrobatidis) Associated with Global Amphibian Declines

Activities of HMR 3787 and RU 64399 Compared with Those of Four Other Agents against Haemophilus influenzae and Haemophilus parainfluenzae

Activities of Garenoxacin (BMS-284756) and Other Agents against Anaerobic Clinical Isolates

A Type II Pathway for Fatty Acid Biosynthesis Presents Drug Targets in Plasmodium falciparum

High-Throughput Growth Assay for Toxoplasma gondii Using Yellow Fluorescent Protein

In Vitro Activities of Cethromycin (ABT-773), a New Ketolide, against Streptococcus pneumoniae Strains That Are Not Susceptible to Penicillin or Macrolides

In Vitro Activity of S-3578, a New Broad-Spectrum Cephalosporin Active against Methicillin-Resistant Staphylococci

In Vitro Drug Interaction Modeling of Combinations of Azoles with Terbinafine against Clinical Scedosporium prolificans Isolates

In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas

Postantibiotic Effects of Garenoxacin (BMS-284756) against 12 Gram-Positive or -Negative Organisms